A visionary in lung oncology: the scientific and human legacy of Prof. Filippo de Marinis
A tribute from one of his former mentees, now a senior oncologist, on the occasion of the 2026 Heine H. Hansen Award presented to de Marinis
Research unlocks insights into lung cancer evolution from electronic medical records
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer
Data from the ELEVATE and ALINA studies highlight the gains provided by adjuvant ALK therapy in patients with ALK-positive disease
Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC
New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
Sacituzumab tirumotecan offers a promising new option for pre-treated EGFR-mutated non-small cell lung cancer
Phase III data show significant survival improvements with the TROP2-directed antibody–drug conjugate after progression on EGFR tyrosine kinase inhibitors
First-line ivonescimab plus chemotherapy improves progression-free survival in squamous NSCLC
Robust efficacy findings and unexpectedly low haemorrhagic events were observed with the bispecific antibody but results will only change practice if benefits translate into overall survival and are replicated beyond China
How therapeutically tractable is MUC1 as a tumour-associated antigen?
Early proof-of-concept is provided showing pan-tumour activity of a novel antibody–drug conjugate
Local consolidative therapy combined with osimertinib improves progression-free survival in metastatic EGFR-mutant NSCLC
Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
Advancing perioperative treatment in resectable non-small cell lung cancer
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting